Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter

Late-Stage Asset Attracts ‘Robust’ Investors

 
• By Mandy Jackson
  
venture capital, text on white paper on wood background
Abcuro moved ABC008 into Phase II/III prior to its series B round • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business